Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aniket Joshi

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Medical Imaging (Bellingham, Wash.)|August 23, 2021
Lung nodule malignancy classification with weakly supervised explanation generationAniket Joshi, Jayanthi Sivaswamy, Gopal Datt Joshi
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 7, 2007
Improving PET receptor binding estimates from Logan plots using principal component analysisAniket Joshi, Jeffrey A Fessler, Robert A Koeppe
Neuroimage|May 22, 2009
Reducing between scanner differences in multi-center PET studiesAniket Joshi, Robert A Koeppe, Jeffrey A Fessler
EJNMMI Research|February 14, 2018
Statistical evaluation of test-retest studies in PET brain imagingRichard Baumgartner, Aniket Joshi, Dai Feng, et al.
Journal of Clinical Medicine|February 13, 2025
Point-of-Care Diagnosis of Atrophic Gastritis by Serological Biomarker Test (GastroPanel<sup>®</sup> Quick Test) in Gastroscopy Referral Patients in IndiaMohinish Chhabra, Ajit Kolatkar, Suresh Chawla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
11C-DTBZ and 18F-FDG PET measures in differentiating dementiasRobert A Koeppe, Sid Gilman, Aniket Joshi, et al.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2015
Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitorsChristopher D Cox, Eric D Hostetler, Broc A Flores, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2015
Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophreniaIzzat T Raheem, John D Schreier, Joy Fuerst, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Medical Imaging (Bellingham, Wash.)|August 23, 2021
Lung nodule malignancy classification with weakly supervised explanation generationAniket Joshi, Jayanthi Sivaswamy, Gopal Datt Joshi
Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|December 7, 2007
Improving PET receptor binding estimates from Logan plots using principal component analysisAniket Joshi, Jeffrey A Fessler, Robert A Koeppe
Neuroimage|May 22, 2009
Reducing between scanner differences in multi-center PET studiesAniket Joshi, Robert A Koeppe, Jeffrey A Fessler
EJNMMI Research|February 14, 2018
Statistical evaluation of test-retest studies in PET brain imagingRichard Baumgartner, Aniket Joshi, Dai Feng, et al.
Journal of Clinical Medicine|February 13, 2025
Point-of-Care Diagnosis of Atrophic Gastritis by Serological Biomarker Test (GastroPanel<sup>®</sup> Quick Test) in Gastroscopy Referral Patients in IndiaMohinish Chhabra, Ajit Kolatkar, Suresh Chawla, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
11C-DTBZ and 18F-FDG PET measures in differentiating dementiasRobert A Koeppe, Sid Gilman, Aniket Joshi, et al.
Annals of the American Thoracic Society|August 22, 2024
Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2, Open-Label Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Annals of the American Thoracic Society|March 21, 2023
Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for <i>F508del-CFTR</i>: A Phase 2 Placebo-controlled Clinical TrialMirjam Stahl, Jobst Roehmel, Monika Eichinger, et al.
Bioorganic & Medicinal Chemistry Letters|June 17, 2015
Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitorsChristopher D Cox, Eric D Hostetler, Broc A Flores, et al.
Bioorganic & Medicinal Chemistry Letters|November 26, 2015
Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophreniaIzzat T Raheem, John D Schreier, Joy Fuerst, et al.
Pageof 2